Renalytix PLC
LSE:RENX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.5
50.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Renalytix PLC
Accounts Receivables
Renalytix PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Renalytix PLC
LSE:RENX
|
Accounts Receivables
$776k
|
CAGR 3-Years
251%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Craneware PLC
LSE:CRW
|
Accounts Receivables
$58.6m
|
CAGR 3-Years
61%
|
CAGR 5-Years
33%
|
CAGR 10-Years
14%
|
||
Cambridge Cognition Holdings PLC
LSE:COG
|
Accounts Receivables
ÂŁ2.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
2%
|
||
Intelligent Ultrasound Group PLC
LSE:IUG
|
Accounts Receivables
ÂŁ2.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
||
EMIS Group PLC
LSE:EMIS
|
Accounts Receivables
ÂŁ50.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
||
Doctor Care Anywhere Group PLC
ASX:DOC
|
Accounts Receivables
ÂŁ1.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
What is Renalytix PLC's Accounts Receivables?
Accounts Receivables
776k
USD
Based on the financial report for Jun 30, 2023, Renalytix PLC's Accounts Receivables amounts to 776k USD.
What is Renalytix PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
251%
Over the last year, the Accounts Receivables growth was -14%. The average annual Accounts Receivables growth rates for Renalytix PLC have been 251% over the past three years .